Vincerx Pharma, Inc. (VINC)
| Market Cap | 236.59K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.65M |
| Shares Out | 5.23M |
| EPS (ttm) | -8.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,376 |
| Average Volume | 130,461 |
| Open | 0.0465 |
| Previous Close | 0.0475 |
| Day's Range | 0.0402 - 0.0512 |
| 52-Week Range | 0.0381 - 17.0000 |
| Beta | 1.45 |
| RSI | 41.72 |
| Earnings Date | Aug 7, 2025 |
About Vincerx Pharma
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 d... [Read more]
Financial Performance
Financial StatementsNews
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
Revised Potential Distribution Range of $0.03 to $0.07 per share based on current estimates and assumptions
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders Failure to approve Dissolution Proposal will reduce or eliminate any potential distribution...
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global...
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings I...
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives
SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. f...
Vincerx Pharma, Inc. Announces Reverse Stock Split
Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vincerx Pharma...
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vincerx Pharma, Inc. (NASDAQ: VINC) and Oqory, Inc. is fair to Vincerx shareholders. Up...
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to learn...
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjuga...
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates
On Monday, Vincerx Pharma VINC shared updates on its ongoing Phase 1 studies of VIP943, VIP236, and enitociclib, which aim to address various blood cancers.
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Pla...
Vincerx Pharma Reports Second Quarter 2024 Financial Results
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected a...
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjuga...
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and...
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common ...
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM ...
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC) Management to host virtual investor event...
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DL...
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2 nd cohort